[The complement system].

L D Taran

Home/Archive/PubMed

PubMed · 8338890

[The complement system].

L D Taran

View original source ↗Export metadata ↓

Abstract

The complement system represents a multitude of activating factors, associated with the cellular membrane and providing for cell lysis. The system is composed of 21 serum proteins and 8 receptors and may be found in cells of various types. The major function of the system consists in its activation which entails a cascade of events terminated by cell lysis. Two complement system activation mechanisms are generally distinguished, one of which is classical and one is alternative. These two mechanisms converge after the activation of the third component (C3) or as a result of interaction between the terminal components (C5, C6, C7, C8 and C9) of the complement cascade. The complement system is linked with the fibrinolytic, blood coagulating and kinin systems.

Explore related subjects

Complement Activation Complement Pathway, Alternative Complement System Proteins Humans English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

L D Taran. 1993. [The complement system].. https://pubmed.ncbi.nlm.nih.gov/8338890/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function.

IgA1 Abs possess conserved N-linked glycosylation sites in the second C region and secreted tailpiece domains. To understand the role of these carbohydrates in the structure and function of human IgA1, site-directed mutants that produce human IgA1 lacking either one or both of the N-linked carbohydrate sites have been produced. When the mutant heavy chains are expressed in myeloma lines producing the relevant kappa-light chain, efficient secretion of the monomer and dimer forms of IgA1 is seen. In addition, higher polymer forms of the IgA molecules lacking the third domain carbohydrate, either singly or in the double mutant, are present. Functional analysis of the IgA1 proteins has shown significant differences between the various mutants and wild-type IgA. The carbohydrate mutants show a reduced affinity for their target Ag, dansyl. All of the IgA1 molecules retained the ability to bind to the polymeric Ig receptor. C3 binding was observed for all of the IgA molecules, with the IgA mutants lacking the third domain carbohydrate showing a reduced ability to bind C3; however, IgA did not effectively activate the alternative pathway, as determined by factor B cleavage and terminal complex binding. These studies demonstrate that N-linked glycosylation in the constant domain of human IgA1 plays an important role in the biologic properties of IgA1.

Complement Activation↗

PubMed1996

Inhibition of classical complement activation by sera from HIV-1-positive patients.

It was shown that gp120/160-coupled CD4+ T cells could be lysed by complement activation, but the target cell lysis was strongly inhibited by the majority of HIV-1-positive sera. Significantly more sera from HIV-1-infected patients with CD4+ T cell count higher than 500 microl (N = 38) as well as from patients with 200-500/microl (N = 32) showed strong inhibition of complement activation as compared to sera from those with less than 200 CD4+ T cells/microl (N = 28) (P = 0.0064 and 0.0012, respectively). Consequently, highly significant correlation between CDL inhibitory activity and CD4+ T cell count in HIV-1-infected patients was found by Spearman's rank order analysis (R = 0.399, P < 0.001). CH50 titer and functional C1-inhibitor level were significantly lower in inhibitory as compared to the noninhibitory sera (P < 0.001) and to controls (P < 0.001). The C3 activation products-C3-circulating immune complexes were not increased in inhibitory sera (P = 0.014) suggesting that inhibition of complement activation occurred at or before C3 activation level. C4d fragments and antigenic C1-INH concentration were significantly increased in both categories of HIV-1-positive sera, P < 0.001. These findings indicate that persistent and massive stimulation of complement system with HIV-1 envelope glycoproteins during all stages of the disease induced impairment of classical pathway activation by an inhibitory factor in a majority of patients, which might contribute to the onset of opportunistic infections and AIDS.

Complement Activation↗

PubMed1996

Neisserial disease.

Explore the source record for details and available documents.

Complement Activation↗